Drug Profile
Research programme: caspase inhibitors - EpiCept
Alternative Names: MX 1153Latest Information Update: 19 Sep 2008
Price :
$50
*
At a glance
- Originator EpiCept Corporation
- Class
- Mechanism of Action Caspase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Multiple organ failure; Myocardial infarction; Septic shock; Stroke
Most Recent Events
- 09 Jan 2006 Maxim Pharmaceuticals has been acquired and merged into EpiCept Corporation
- 22 Aug 2005 This programme is still in active development
- 19 Jul 2000 Cytovia has been acquired by Maxim Pharmaceuticals